ValuEngine cut shares of Nuvectra Corporation (NASDAQ:NVTR) from a hold rating to a sell rating in a report issued on Monday.

NVTR has been the subject of several other reports. Zacks Investment Research raised shares of Nuvectra Corporation from a sell rating to a hold rating in a research report on Wednesday, July 12th. Piper Jaffray Companies restated a neutral rating and issued a $14.00 target price on shares of Nuvectra Corporation in a research note on Thursday, July 6th. Finally, TheStreet raised shares of Nuvectra Corporation from a d rating to a c- rating in a research report on Monday, June 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $10.50.

Nuvectra Corporation (NVTR) opened at 13.21 on Monday. The company’s 50 day moving average is $12.24 and its 200 day moving average is $12.24. Nuvectra Corporation has a 12 month low of $4.63 and a 12 month high of $13.41. The stock’s market cap is $141.33 million.

Nuvectra Corporation (NASDAQ:NVTR) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($1.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.14) by $0.07. The company had revenue of $7.20 million for the quarter, compared to the consensus estimate of $5.96 million. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The firm’s revenue was up 188.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.85) EPS. On average, analysts anticipate that Nuvectra Corporation will post ($4.77) EPS for the current fiscal year.

WARNING: “Nuvectra Corporation (NVTR) Lowered to “Sell” at ValuEngine” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/nuvectra-corporation-nvtr-lowered-to-sell-at-valuengine/1605024.html.

In other news, CEO Scott F. Drees bought 10,000 shares of the stock in a transaction on Friday, August 11th. The stock was acquired at an average cost of $11.72 per share, for a total transaction of $117,200.00. Following the acquisition, the chief executive officer now owns 125,180 shares of the company’s stock, valued at $1,467,109.60. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.60% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Gamco Investors INC. ET AL increased its stake in shares of Nuvectra Corporation by 4.2% during the second quarter. Gamco Investors INC. ET AL now owns 35,194 shares of the company’s stock valued at $467,000 after buying an additional 1,434 shares during the period. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Nuvectra Corporation by 12.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 953,431 shares of the company’s stock valued at $12,662,000 after acquiring an additional 105,580 shares in the last quarter. Rockefeller Financial Services Inc. raised its holdings in shares of Nuvectra Corporation by 3.2% in the second quarter. Rockefeller Financial Services Inc. now owns 107,523 shares of the company’s stock valued at $1,428,000 after acquiring an additional 3,338 shares in the last quarter. FNY Partners Fund LP raised its holdings in shares of Nuvectra Corporation by 15.1% in the first quarter. FNY Partners Fund LP now owns 98,200 shares of the company’s stock valued at $670,000 after acquiring an additional 12,900 shares in the last quarter. Finally, EAM Investors LLC bought a new stake in shares of Nuvectra Corporation in the second quarter valued at about $752,000. 57.42% of the stock is currently owned by institutional investors and hedge funds.

About Nuvectra Corporation

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.